BioSpace News Archive

Autobahn Therapeutics today announced that Kevin Finney, President and Chief Executive Officer, will participate in two upcoming investor conferences.

Propanc Biopharma, Inc. today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 and recent business highlights.

Cerevance today announced participation at the upcoming TD Cowen 44th Annual Health Care Conference, taking place at the Boston Marriott Copley Place in Boston, MA from March 4-6, 2024. Company management will host one-on-one meetings during the conference.

ChemoMouthpiece, LLC. announces the FDA 510 Marketing Clearance for their device, The Chemo Mouthpiece™.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”) is pleased to announce that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimer’s Disease.

SOPHiA GENETICS (Nasdaq: SOPH) today announced Co-founder and Chief Executive Officer, Dr. Jurgi Camblong, and Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. EDT.

Agile Therapeutics, Inc. today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per share, at a reduced exercise price of $1.25 per share.

NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

BostonGene Appoints Joe Lennerz, MD, PhD, as Chief Scientific Officer, Mark Hiatt, MD, MBA, MS as Senior Vice President of Market Access and Strategy and Ned Segal as Board Member.